DXCM · DexCom, Inc.

Dexcom's 2026 Investor Day featured new long-range financial targets signaling sustained growth and margin expansion, with organic revenue targeted at 10%+ annually through 2030, culminating in non-GAAP gross margins of 67-69%, operating margins of 29-30%, and adjusted EBITDA margins of 36-37%. These aspirations reflect confidence in market opportunities, business strategy, and innovation efforts discussed at the event. Concurrently, the Board approved a $1.0 billion share repurchase program for common stock, terminating the prior program with $250 million remaining, providing flexibility for open market or negotiated repurchases under Rules 10b5-1 and 10b-18 through June 30, 2027. Repurchases are discretionary, dependent on market conditions, and can be modified or suspended. Item 7.01 disclosure is furnished, not filed, underscoring its forward-looking nature with noted uncertainties and non-GAAP definitions in prior filings. This combination enhances shareholder value through growth prospects and capital returns.